Scripps hopes for royalty windfall from potential blockbuster drug

If the new drug Ozanimod achieves blockbuster status, it could generate tens of millions of dollars a year in royalties for the Scripps Research Institute.  Ozanimod, a drug that slows brain atrophy in patients with multiple sclerosis, was discovered at Scripps and is expected to be marketed by Celgene (Nasdaq: CELG) to MS patients in late 2018.